This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Biosimilar Adalimumab (Innovent)
Innovent Biologics, Inc.
Drug Names(s): IBI303, IBI 303, IBI-303, biosimilar adalimumab, biosimilar Humira
Innovent's compound is a biosimilar to AbbVie's Humira. Humira (adalimumab) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). Humira binds specifically to TNF-alpha and blocks interaction with the p55 and p75 cell surface TNF receptors. Humira also lyses surface TNF expressing cells in the presence of complement.
IBI303 is an investigational fully human IgG1 antibody that binds to and neutralizes the inflammatory cytokine TNF-a.
Biosimilar Adalimumab (Innovent) News
Additional information available to subscribers only: